Literature DB >> 16831692

Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT.

Chun-Jen Liu1, Ding-Shinn Chen, Pei-Jer Chen.   

Abstract

Hepatitis B virus (HBV) infection is endemic in many Asian countries. Among many transmission routes, transfusion is the one that should be prevented. The first major success in enhancing transfusion safety came with the implementation of hepatitis B surface antigen (HBsAg) in the early 1970s. However, the studies quoted in this review demonstrate that transmission by blood components negative for HBsAg can still occur in the acute phase of infection during the seronegative window period, or during chronic stages of infection (i.c. "occult" HBV infection, OHB). OHB is defined as the presence of HBV DNA in blood or liver tissues in patients negative for HBsAg, with or without any HBV antibodies. Because of limitations in current blood screening practices, OHB is an overlooked source of HBV transmission. For policy development on screening for HBV infection in blood donors, it would be useful to assess the relative contribution of the above two sources of transfusion-transmitted HBV infection from HBsAg-negative donations. New screening policy should be evaluated on the basis of available data or newly designed studies. While anti-HBc screening can climinate residual risk of occult HBV transmission by transfusion in low-endemic areas, it would not be practical in most parts of the world where the prevalence of anti-HBc is >10% as too many otherwise healthy donors will be ineligible. On the contrary, studies mentioned in this paper indicate that nucleic acid amplification test (NAT) or new HBsAg tests of enhanced sensitivity would be effective in the screening of blood donors for OHB in highly endemic countries. However, the cost-effectiveness of blood screening tests is a major concern in Asia. We therefore have systemically reviewed the literature on prevalence and infectivity of OHB in Asian countries and the possible role of NAT for identifying blood donors in the pre-HBsAg window phase or in later stages of OHB.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831692     DOI: 10.1016/s1386-6532(06)80007-7

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  30 in total

1.  Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-06-14       Impact factor: 6.047

Review 2.  Molecular mechanisms underlying HBsAg negativity in occult HBV infection.

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-24       Impact factor: 3.267

3.  Occult hepatitis B demonstrated by anti-HBc and HBV DNA in HIV-positive patients.

Authors:  Arezoo Honarmand; Morteza Pourahmad; Kavous Solhjoo; Mahmoud Kohan; Mohamad Hassan Davami; Seyed Kamyar Mostafavi Zadeh
Journal:  Rep Biochem Mol Biol       Date:  2014-10

Review 4.  Optimizing antiviral agents for hepatitis B management in malignant lymphomas.

Authors:  Oluwatobi O Ozoya; Julio Chavez; Lubomir Sokol; Samir Dalia
Journal:  Ann Transl Med       Date:  2017-02

Review 5.  Pathogenesis of occult chronic hepatitis B virus infection.

Authors:  Rocio Aller de la Fuente; María L Gutiérrez; Javier Garcia-Samaniego; Conrado Fernández-Rodriguez; Jose Luis Lledó; Gregorio Castellano
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

Review 6.  MicroRNAs as therapeutic strategy for hepatitis B virus-associated hepatocellular carcinoma: current status and future prospects.

Authors:  Yi Lin Jane Tan; Wei Ning Chen
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

7.  Prevalence of occult hepatitis B infection in patients visiting tertiary care hospital.

Authors:  A K Sood; Chetan Pangotra; Manish Manrai
Journal:  Med J Armed Forces India       Date:  2016-04-18

Review 8.  Molecular testing in the diagnosis and management of chronic hepatitis B.

Authors:  Alexandra Valsamakis
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

9.  Occult hepatitis B virus infection among Egyptian blood donors.

Authors:  Zeinab N Said; Manal H El Sayed; Iman I Salama; Enas K Aboel-Magd; Magda H Mahmoud; Maged El Setouhy; Faten Mouftah; Manal B Azzab; Heidi Goubran; Amal Bassili; Gamal E Esmat
Journal:  World J Hepatol       Date:  2013-02-27

10.  Occult hepatitis B virus infection as a cause of posttransfusion hepatitis in patients with cancers.

Authors:  Jaswinder Singh Sodhi; Nayeem Wani; Samoon Jeelani; Sajad Geelani; Fehmida Akhtar; Gul Javid; Gh Nabi Yattoo; Altaf Shah; Gh Mohd Gulzar; Mushtaq A Khan; Shaheena Parveen; Riyaz-U Saif; Abid Showkat
Journal:  Indian J Gastroenterol       Date:  2013-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.